CD55-deficiency in Jews of Bukharan descent is caused by the Cromer blood type Dr(a-) variant.
Journal
Human genetics
ISSN: 1432-1203
Titre abrégé: Hum Genet
Pays: Germany
ID NLM: 7613873
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
31
10
2021
accepted:
27
12
2021
medline:
15
5
2023
pubmed:
23
3
2022
entrez:
22
3
2022
Statut:
ppublish
Résumé
The complement system regulator CD55 was initially found to carry the Cromer blood group system antigens, and its complete loss of function was subsequently revealed to cause a severe monogenic gastrointestinal syndrome characterized by protein-losing enteropathy and susceptibility to venous thrombosis. Here we present homozygosity to the CD55 c.596C>T; p.Ser199Leu variant, which was previously described as the Cromer Dr(a-) genotype, in two Bukharan Jewish CD55-deficiency patients with variable disease severity. We confirm that this missense variant causes aberrant splicing and deletion of 44 bp in exon 5, leading to premature termination and low expression of the CD55 protein. Furthermore, Patient 1 exhibited a mildly abnormal B cell immunophenotyping profile. By population screening we established that this variant is highly prevalent in the Bukharan Jewish population, with a carrier frequency of 1:17, suggesting that many similar patients are un- or mis-diagnosed. The phenotypic variability, ranging from abdominal pain when eating a high-fat diet to the full CD55-deficiency phenotype, is likely related to modifiers affecting the proportion of the variant that is able to escape aberrant splicing. Establishing the diagnosis of CD55-deficiency in a timely manner, even in patients with milder symptoms, may have a critical effect on their management and quality-of-life since treatment with the complement inhibitor eculizumab is highly effective in ameliorating disease manifestations. Awareness of founder mutations within certain populations can further guide genetic testing and prevent a diagnostic odyssey, by placing this CD55 variant high on the differential diagnosis.
Identifiants
pubmed: 35314883
doi: 10.1007/s00439-021-02428-3
pii: 10.1007/s00439-021-02428-3
pmc: PMC8936040
doi:
Substances chimiques
CD55 Antigens
0
Blood Group Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
683-690Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Nat Rev Immunol. 2009 Oct;9(10):729-40
pubmed: 19730437
J Clin Immunol. 2021 Feb;41(2):477-481
pubmed: 33215321
Sci Adv. 2021 Mar 31;7(14):
pubmed: 33789895
Mol Immunol. 2019 Oct;114:341-352
pubmed: 31446305
Blood. 1994 Aug 15;84(4):1276-82
pubmed: 7519480
Transfusion. 2006 Sep;46(9):1537-42
pubmed: 16965581
Blood. 1991 Dec 15;78(12):3291-7
pubmed: 1720702
J Clin Invest. 1991 Jun;87(6):1945-52
pubmed: 1710232
Orphanet J Rare Dis. 2008 Feb 22;3:5
pubmed: 18294365
Nature. 2021 Sep;597(7875):263-267
pubmed: 34408323
Nat Immunol. 2021 Feb;22(2):128-139
pubmed: 33398182
J Pediatr Gastroenterol Nutr. 2019 Mar;68(3):325-333
pubmed: 30418410
Clin Immunol. 2006 Feb-Mar;118(2-3):127-36
pubmed: 16338172
N Engl J Med. 2017 Jul 6;377(1):52-61
pubmed: 28657829
N Engl J Med. 2017 Jul 6;377(1):87-89
pubmed: 28657861
Immunohematology. 2010;26(3):109-18
pubmed: 21214297
Blood. 2000 Nov 15;96(10):3522-8
pubmed: 11071650
Transfus Med. 1998 Jun;8(2):141-7
pubmed: 9675792
Immunohematology. 2005;21(2):39-47
pubmed: 15954803
Methods Mol Biol. 2016;1402:229-241
pubmed: 26721495
Transfusion. 1984 Jan-Feb;24(1):13-5
pubmed: 6695433